Company Interview / A year's worth of work pays off

Dr Daniel Tillett from Race Oncology (ASX: RAC) shares insights on its phase one trial progress. Race has submitted an ethics package for solid tumour treatment, setting up for early 2025 patient enrolment in a phase one clinical trial. Daniel says it is a year's worth of work, finally paying off.

Race Oncology is revisiting an effective 1980s drug, abandoned due to delivery issues. They've innovated a new formulation enhancing patient delivery, gaining new IP and patents. Daniel says phase one now promises better outcomes, boosted by the drug's tested history and dual benefits.

Daniel emphasises the cardiovascular benefits of their reformulated drug, proposing it combats cancer while protecting the heart. Highlighting chemotherapy's permanent cardiac damage, he shares optimism for improved patient outcomes and reduced treatment-related disabilities.